Tirzepatide for Methamphetamine Addiction

(T-STEM Trial)

This trial tests tirzepatide, a medication, to determine its effectiveness in helping people with moderate or severe methamphetamine addiction. Researchers aim to assess its safety and efficacy in reducing methamphetamine use. Participants will receive weekly injections and undergo various assessments over 32 weeks. The trial seeks individuals with an active pattern of methamphetamine use who are interested in quitting or reducing their use and are overweight or obese. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Research has shown that tirzepatide has undergone safety testing in people, particularly those with obesity. These studies found tirzepatide to be effective and generally safe. Some participants experienced side effects, but these were usually mild and manageable. This suggests tirzepatide is likely well-tolerated, though individual experiences may vary. As this trial is in an early stage, it primarily aims to assess the safety and tolerability of tirzepatide for treating methamphetamine use disorder.¹²³⁴⁵

Tirzepatide is unique because it offers a fresh approach to tackling methamphetamine addiction, an area where current treatments like behavioral therapies and medications such as bupropion and naltrexone often fall short. Unlike these standard options, tirzepatide is a medication originally used for diabetes and obesity, which works by activating both the GIP and GLP-1 receptors involved in appetite regulation and reward pathways. This dual action mechanism could potentially reduce cravings and withdrawal symptoms, giving it an edge in treating addiction. Researchers are excited about tirzepatide's potential because it represents a new class of treatment with a different mechanism that could bring hope to those struggling with methamphetamine addiction.

Research has shown that tirzepatide, a drug primarily used for weight loss and diabetes, might also aid in treating methamphetamine addiction. In this trial, some participants will receive tirzepatide to assess its effectiveness for methamphetamine use disorder (MtUD). Studies have found that similar drugs, such as semaglutide, can reduce issues related to substance use. Early evidence suggests that tirzepatide could help individuals with MtUD by lessening cravings and supporting early remission, which involves reduced drug use. Other research indicates that medications like tirzepatide can decrease the incidence of new substance use cases. Although further research is necessary, these findings suggest tirzepatide could be a promising option for those facing methamphetamine addiction.¹²³⁴⁶